Stock KA KINETA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Kineta, Inc.

Equities

KA

US49461C1027

Market Closed - Nasdaq
Other stock markets
 16:30:01 2024-05-20 EDT 		5-day change 1st Jan Change
0.481 USD +6.42% Intraday chart for Kineta, Inc. -7.50% -86.75%
04-08 Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial CI
03-21 Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities
AQ
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
AQ
Kineta, Inc. Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 Vista-101 Clinical Trial
CI
Earnings Flash (KA) KINETA Posts 2023 Revenue $5.4M
MT
Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update
AQ
KVA12123 Clears Additional Cohorts in Monotherapy and in Combination Therapy Arms in the Phase 1/2 VISTA-101 Clinical Trial; Initial Clinical Response Data Reported
AQ
Kineta, Inc. Announces an Update on Its Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating Kva12123
CI
Top Midday Decliners
MT
Kineta Announces Restructuring and Exploration of Strategic Alternatives
AQ
Kineta, Inc. Terminates Employment of Pauline Kenny as General Counsel and Secretary
CI
Kineta, Inc. Terminates Employment of Shawn Iadonato as CEO
CI
Kineta, Inc. Announces Restructuring and Workforce Reduction
CI
Kineta Announces Exploration of Strategic Alternatives
CI
Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium
AQ
Kineta to Present at Upcoming Investor Conferences
AQ
Kineta to Participate in H.C. Wainwright Virtual @Home Fireside Chat Series
AQ
Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors
AQ
Kineta, Inc. Announces Update on Ongoing Vista-101 Phase 1/2 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Tumor Activity
CI
Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event
AQ
Kineta Publishes Preclinical Data Demonstrating the Potential of Anti-VISTA Antibody KVA12123 as an Immunomodulatory Therapy for Cancer
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KA Stock
  4. News Kineta, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW